Corona Remedies Reports Robust Q2 FY27, Revenue Up 22.2% To ₹441.2 Crore; Chronic Business Drives Growth

Mumbai - Syrma SGS Technology reported strong financial results for the second quarter and half-year of Fiscal Year 2027, with net profit surging by an impressive 87.2% and revenue growing by 73.2%. The company's consolidated net profit for Q2 FY27 reached ₹124.2 crore, compared to ₹66.3 crore in the same quarter last year. Total consolidated revenue stood at ₹1,999.5 crore, a 73.2% increase from ₹1,154.6 crore in Q2 FY26.

Half-yearly figures showed a even more remarkable 97.7% increase in net profit to ₹229.9 crore, up from ₹116.3 crore in H1 FY26. Operating revenue for the first half of the fiscal year grew by 70.9% to ₹3,603.2 crore, up from ₹2,108.7 crore. EBITDA and EBITDA margins improved, with Q2 FY27 EBITDA at ₹203.1 crore, up 63.9% from ₹124 crore, and a margin of 10.2%, down slightly from 10.5%.

Export revenue accounted for 26% of operating revenue in Q2 FY27, a 91% year-on-year increase. For H1 FY27, export revenue was 25% of operating revenue, up 80% year-on-year. CEO Jasbir Singh Gujral attributed the growth to strong performance in automotive and industrial sectors, along with an 80% rise in exports. The company also unveiled a new facility in Bengaluru for its joint venture and Syrma Johari MedTech opened a new facility in Jodhpur to support medical-device programs.